Cytokine networks with infection: Mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 205-223

  DiPiro, Joseph T ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; INTRADERMAL DRUG ADMINISTRATION; KAPOSI SARCOMA; LEISHMANIA; LEISHMANIASIS; LEPROSY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; SEPSIS;

ANIMALS; CYTOKINES; GRAM-NEGATIVE BACTERIA; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKINS; LEISHMANIASIS; MYCOBACTERIUM INFECTIONS; SEPSIS; TH1 CELLS; TH2 CELLS;

EID: 0030939080     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-82.
2. Kay AB. Origin of type 2 helper T cells. N Engl J Med 1994;330:567-9.
3. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995;16:76-80.
4. Manetti R, Annunziato F, Biagiotti R, et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+T cell clones in human immunodeficiency virus infection. J Exp Med 1994;180:2407-11.
5. Hamann D, Hilkens CMU, Grogan JL, et al. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996;156:1387-91.
6. Legac E, Autran B, Merle-Beral H, Katlama C, Debre P. CD4+CD7- CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood 1992;7:1746-53.
7. Gallin JI, moderator. Interferon-γ in the management of infectious diseases. Ann Intern Med 1995;123:216-24.
8. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-γ. J Immunol 1985;134:1619-22.
9. Parronchi P, DeCarli M, Manetti R, et al. IL-4 and INF (α and γ) exert opposite regulatory effects on the development of cytolytic potential of Th1 or Th2 human T cell clones. J Immunol 1992;149:2977-83.
10. Trincheri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993;14:335-7.
11. Huang S, Hendriks, W, Althage A, et al. Immune response in mice that lacks the interferon-γ receptor. Science 1993;259:1742-5.
12. Kamijo R, Le J, Shapiro D, et al. Mice that lack the interferon-γ receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and to subsequent challenge with lipopolysaccharide. J Exp Med 1993;178: 1435-40.
13. Reiner SL, Locksley RM. Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis. J Cell Biochem 1993;53:323-8.
14. Marx J. Leishmania susceptibility puzzle gets another twist. Science 1996;271:912-13.
15. Dunlap NE, Briles DE. Immunology of tuberculosis. Med Clin North Am 1993;77:1235-51.
16. Nathan CFG, Murray HW, Wiebe MA, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-89.
17. Bermudez LEM, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988;140:3006.
18. Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974;56:494-505.
19. Onwubalili JK, Scott GM, Robinson JA. Deficient immune interferon production in tuberculosis. Clin Exp Immunol 1985;59:405-13 .
20. Toosi Z, Kleinhenz ME, Ellner JJ. Defective interleukin 2 and responsiveness in human pulmonary tuberculosis. J Exp Med 1986;163:1162-72 .
21. Flynn JL, Goldstein MM, Triebold KJ, et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995;155:2515-24.
22. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and INFγ in tuberculosis patients. J Immunol 1990;145:149-54.
23. Barnes PF, Lu S, Abrams S, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993;61:3482-9.
24. Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994;93:1733-39.
25. Normile D. IL-12 at the crossroads. Science 1995;268: 1432-3.
26. Cooper AM, Roberts AD, Rhoades ER, et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995;84:423-32.
27. Surcel HM, Trpye-Blomberg M, Paulie S, et al. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994;81:171-6.
28. Sieling PA, Abrams JS, Yamamura M, et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol 1993;150:5501-10.
29. Zhang M, Lin Y, lyer DV, et al. T cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995;63:3231-4.
30. Kaplan G. Recent advances in the treatment of leprosy. J Infect Dis 1993;167(suppl):S118-22.
31. Modlin RL, Hofman FM, Horwitz DA, et al. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 1984;132:3085-90.
32. Sieling PA, Modlin RL. Regulation of cytokine patterns in leprosy. Ann NY Acad Sci 1994;730:42-52.
33. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991;254:277-9.
34. Flad HD, Richter E, Schluter C, et al. Mycobacterium leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy. Immunobiology 1994;191:388-94.
35. Khanolkar-Young S, Rayment N, Brickell PM, et al. Tumor necrosis factor-alpha (TNF alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995;99:196-202.
36. Mutis T, Kraakman EM, Cornelisse YE, et al. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific non-responsiveness of peripheral blood T cells from lepromatous leprosy patients. J Immunol 1993;150:4641-51.
37. Fink S, de la Barrera S, Minnucci F, et al. IFN-gamma, IL-6, IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. Scand J Immunol 1993;38:551-8.
38. Kaplan G, Britton WJ, Hancock CE, et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991;173:993-1006.
39. Bermudez LE, Kaplan G. Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 1995;3:22-7.
40. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.
41. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-γ in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15.
42. Kaplan G, Mathur NK, Job CK, et al. Effect of multiple interferon-γ injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci USA 1989;86:8073-7.
43. Pearson RD, Sousa AQ. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996;22:1-13.
44. Sacks DL, Lal SL, Shrivastava SN, et al. An analysis of T cell responsiveness in Indian kala-azar. 1987;138:980-13.
45. Locksley RM, Scott P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol Today 1991;12:A58-61.
46. Titus RG, Sherry B, Cerami A. The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites. Immunol Today 1991;12:A13-16.
47. Liew FY, Parkinson C, Millot S, Severn A, Carrier M. Tumor necrosis factor in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 1990;69:570-3.
48. Titus RG, Sherry B, Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989;170:2097-2104.
49. Sadick MD, Locksley RM, Tubbs C, Raff HV. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol 1986;136:655-61.
50. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J Exp Med 1989;169:59-72.
51. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
52. Hall SS. IL-12 at the crossroads. Science 1995;268:1432-4,
53. Sypeck JP, Chung CL, Mayor SEH, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993;177: 1797-1802.
54. 2 production and antileishmanial capacity of human cultured monocytes mediated by INF gamma. J Immunol 1989;143:3020-4.
55. Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti-INF gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989;143:266-74.
56. Sadick MD, Heinzel FP, Holaday BJ, et al. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 1990;171:115-27.
57. H1 cell development. Science 1996;271:984-7.
58. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in interleukin-4 deficient mice. Science 1996;271:987-90.
59. Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci USA 1993;90:3442-6.
60. Skeiky YA, Guderian JA, Benson DR, et al. A recombinant antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995;181:1527-37.
61. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceição-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993;91:1390-5.
62. Caceres-Dittmar G, Tapia FJ, Sanchez MA, et al. Determination of the cytokine profile in American cutaneous leishmaniasis using polymerase chain reaction. Clin Exp Immunol 1993;91:500-5.
63. Carvalho EM, Badaro R, Reed SG, et al. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985;76:2066-9.
64. Ghalib HW, Whittle JA, Kubin M, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 1995;154:4623-9.
65. Ghalib HW, Piuvezam MR, Skeiky YA, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993;92:324-9.
66. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993;5:524-31.
67. Karp CL, El-Safi H, Wynn TA, et al. In vivo cytokine profiles in patients with kala-azar. J Clin Invest 1993;91:1644-8.
68. Kurkcuoglu N, Tandogdu R. Interferon gamma therapy for cutaneous leishmaniasis [letter]. Arch Dermatol 1990;126:831-2.
69. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high dose meglumine antimonate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994;18:381-4.
70. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ. J Infect Dis 1994;170:659-62.
71. Badaro R, Johnson WD. The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993;167(suppl 1):S13-17.
72. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322:16-21.
73. Nutman TB. Protozoal infections and hyper-IgE states. Ann Intern Med 1995;123:221-2.
74. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;12:575-81.
75. Lucey DR, Elcher GP, Hendrix CW, et al. Human immunodeficiency virus infection in the U.S. Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991;164:631-7.
76. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with human immunodeficiency virus. J Clin Invest 1994;93:768-75.
77. H2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14: 107-11.
78. Ameglio F, Cordiali FP, Solmone M, et al. Serum IL-10 levels in HIV-positive subjects: correlation with CDC stages. J Biol Regul Homeost Agents 1994;8:48-52.
79. Angel JB, Saget BM, Wang MZ, Wang A, Dinarello CA, Skolnick PR. Interleukin 10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. J Interferon Cytokine Res 1995;15:573-84.
80. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:442-9.
81. Paginelli R, Scala E, Ansotegui IJ, et al. CD8+ T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE. J Exp Med 1995;181:423-8.
82. Isreal-Biet D, Labrousse F, Tourani JM, Sors H, Andrien JM, Even P. Elevation of IgE in HIV-infected subjects: a marker for poor prognosis. J Allerg Clin Immunol 1992;89:68-75.
83. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a Th1 to ThO shift and to replicate preferentially in Th2 and Th0 cell. Science 1994;265:244-8.
84. Trinchieri G, Wysocka M, D'Andrea A, et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res 1992;4:355-68.
85. Trincheri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994;15:460-3.
86. Hyjeck E, Lischner H, Hyslop T, et al. Cytokine patterns during progression to AIDS in children with perinatal infection. J Immunol 1995;155:4060-71.
87. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76-94.
88. Clouse KA, Powell D, Washington I, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989;142:431-8.
89. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T cell clone. Proc Natl Acad Sci USA 1989;86:2365-8.
90. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today 1990;11:176-80.
91. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 1995;154:3582-92.
92. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest 1995;95:1723-34.
93. Clerici M, Sarin A, Coffman RL, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994;91:11811-15.
94. Vyakaram A, Matear PM, Martin SJ, Roitt I. HIV replication inhibited by TH1 but not TH2 CD4+ T cell clones specific for HIV-1 gag p24. Presented at the 11th International Conference on AIDS, Berlin, Germany, June 6-11, 1993.
95. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 1994;265:248-52.
96. Thea DM, Porat R, Nagimbi K, et al. Plasma cytokine, cytokine antagonists, and disease progression in African women infected with HIV 1. Ann Intern Med 1996;124: 757-62.
97. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus -1 replication by transcriptional activation at the long term repeat. J Clin Invest 1995;95:2324-31.
98. Wallis RS, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV): enhanced cytokine expression and elevated beta-2-microglobulin in HIV-1 associated tuberculosis. J Infect Dis 1993;168:1327-8.
99. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-75.
100. Locksley RM. Interleukin 12 in host defense against microbial pathogens. Proc Nat Acad Sci USA 1993;90: 5879-80.
101. Cohen J. IL-12 deaths: explanations and a puzzle. Science 270;1995:908,
102. Cue JI, DiPiro JT, Brunner LJ, et al. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor a responses to lipopolysaccharide in rabbits. Arch Surg 1994;129:193-7.
103. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH. The complex pattern of cytokines in sepsis. Ann Surg 1991;214:141-8.
104. Mitchie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-6.
105. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
106. Buetler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985;229:869-71.
107. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
108. Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.
109. Gardlund B, Sjolin J, Nilsson A, et al. Plasma levels of cytokines in primary septic shock in humans: correlation with disease activity. J Infect Dis 1995;172:296-301.
110. Dinarello CH, Wolff SM. The role off interleukin-1 in disease. N Engl J Med 1993;328:106-13.
111. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis.1991;163:1177-84.
112. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high dose carboplatin. N Engl J Med 1993;328:756-61.
113. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995;171:145-52.
114. Steinmetz HT, Herbertz A, Bertram M, Diehl V. Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis. J Infect Dis 1995;171:225-8.
115. Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with cytokines. Am J Med 1991;91:23-9.
116. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993;119:771-8.
117. Hack CE, DeGroot ER, Felt-Bersma JF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74: 1704-10.
118. Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during severe sepsis in humans; IL-6 as a marker of severity. Ann Surg 1992;215:356-62.
119. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
120. Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988;108:595-608.
121. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for INFγ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J Immunol 1992;149:1666-70.
122. Redmond HP, Chavin KD, Bromberg JS, Daly JM. Inhibition of macrophage-activating cytokines is beneficial in acute septic response. Ann Surg 1991;214:502-9.
123. Hershman MJ, Polk HC, Pietsch JD, Shields RE, Wellhausen SR, Sonnenfeld G. Modulation of infection by gamma interferon treatment following trauma. Infect Immun 1988;56:2412-16.
124. Chromarat P, Rissoan MC, Banchereau J, Miossec P. Interferon γ inhibits interleukin 10 production by monocytes. J Exp Med 1993;177:523-7.
125. Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309-12.
126. O'Mahony JB, Palder SB, Wood JJ, et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma 1984;24:869-75.
127. Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, Baue AE. Depression of cellular immunity after major injury. Arch Surg 1986;121:1000-5.
128. Hack CE, Hart M, Strack RJM, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-42.
129. Martich GD, Danner RL, Ceska M, Suffrendi AF. Detection of IL-8 and TNFα in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991;173:1021-4.
130. Marty C, Misset B, Tamion F, Fitting C, Carlet J, Cavaillon JM. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Crit Care Med 1994;22:673-9.
131. Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete chemokine interleukin-8 in response to bacterial entry. Infect Immun 1993;61:4569-74.
132. Vogels MTE, van der Meer JWM. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob Agents Chemother 1992;36:1-5.
133. McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the granulocyte/ macrophage colony-stimulating factor and tumor necrosis factor. J Exp Med 1992;176:593-8.
134. Fischer E, Vann Zee KJ, Marano MA, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992;79:2916-2200.
135. Muzio M, Re F, Sironi M, et al. Interleukin-13 induces the production of interleukin-1 receptor antagonist (IL-1ra) and the expression of the mRNA for the intracellular (keratinocyte) form of IL-1ra in human myelomonocytic cells. Blood 1994;83:1738-43.
136. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) up regulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994;179:1695-9.
137. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
138. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991;5:338-43.
139. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin 1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
140. Mancilla J, Garcia P, Dinarello CA. The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 1993;61:926-32.
141. Opal SM, Cross AS, Jhung JW, et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 1996;173:1415-21.
142. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxemia. Lancet 1991;338:1423-4.
143. Granowitz EV, Porat R, Mier JW, et al. Hematologic and immunomodulatory effects of interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993;82:2985-90.
144. Fenton MJ, Buras JA, Donnelly RP. IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol 1992;149:1283-8.
145. Orino E, Sone S, Nii A, Ogura T. IL-4 up-regulates IL-1 receptor antagonist gene expression and its production in human blood monocytes. J Immunol 1992;149:925-31.
146. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992;89:4076-80.
147. Vercelli D, Jabara HH, Lauener RP, Geha RS. IL-4 inhibits the synthesis of INFê and induces the synthesis of IgE in human mixed lymphocyte cultures. J Immunol 1990;144: 570-3.
148. Peleman R, Wu J, Fargas C, Delespesse G. Recombinant interleukin 4 suppresses the production of interferon γ by human mononuclear cells. J Exp Med 1989;170:1751-6.
149. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/INFγ release while increasing IL-4/IL-10 production. J Surg Res 1994;56: 579-85.
150. DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger AR. Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg 1995;130:1159-63.
151. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995;222:482-92.
152. Howard M, O'Garra A. Biologic properties of interleukin 10. Immunol Today 1992;13:198-200.
153. Van der Poll T, Marchant A, Buurman WA, et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995;155:5397-5401.
154. Krakauer T. Differential inhibitory effects of interleukin-10, interleukin-4, and dexamethasone on staphylococcal enterotoxin-induced cytokine production on T cell activation. J Leukocyte Biol 1995;57:450-4.
155. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood. 1994;83:2678-83.
156. Malefyt RDW, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
157. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995;181: 1887-92.
158. Rogy MA, Auffenberg T, Espat NJ, et al. Human tumor necrosis receptor (p55) and interleukin 10 gene transfer in the mouse reduce mortality to lethal endotoxemia and also attenuate local inflammatory responses. J Exp Med 1995;181:2289-93.
159. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-50.
160. Standiford TJ, Strieter RM, Lukas NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-9.
161. Bean AGD, Freiberg RA, Andrade S, Menon S, Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993;61:4937-9.
162. Kato T, Murata A, Ishida H, et al. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 1995;39:1336-40.
163. Van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJ. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994;180:1985-8.
164. Gomez-Jimenez J, Martin MC, Sauri R, et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995;171:472-5.
165. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995;171: 229-32.
166. Sherry RM, Cue JI, Goddard JK, DiPiro JT. Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 1966;40:613-17.
167. Pollmacher T, Korth C, Mullington J, et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87:900-5.
168. Calvano SE, van der Poll T, Coyle SM, Barie PS, Moldawer LL, Lowry SF. Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg 1996;131: 434-7.
169. Ertel W, Keel M, Bonaccio M, et al. Release of antiinflammatory mediators after mechanical injury correlates with severity of injury and clinical outcome. J Trauma 1995;39:879-85.
170. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Patterns of soluble TNF receptors I and II in sepsis. Infection 1995;23:143-8.
171. Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The sepsis intervention group. JAMA 1995;274:172-7.
172. Fisher CJ Jr, Dhainault JF, Pribble JP, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Result of a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Study Group. JAMA 1994;27:1836-43.
173. Stack AM, Saladino RA, Thompson C, et al. Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med 1995;23:1512-18.
174. Fisher CJ Jr, Opal SM, Dhainaut J-F, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27.
175. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995;154:5492-9.